Can a new drug shrink Hard-to-Treat cancers? an early trial seeks answers

NCT ID NCT04511845

Completed Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called SPYK04 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for early signs that SPYK04 can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called SPYK04
What this could lead to: If SPYK04 proves safe and shows signs of shrinking tumors, it could lead to a new treatment option for people with advanced solid cancers that have stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) trial with a small number of participants, so the drug may turn out to be ineffective or have unacceptable side effects. It is far from being a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS MUTATED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Arizona Oncology

Tucson, Arizona, 85711, United States
Cancer Institute Hospital of Japanese Foundation for Cancer Research

Koto-Ku, Tokyo, 135-8550, Japan
Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Kurume University Hospital

Kurume, Fukuoka, 830-0011, Japan
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Minnesota Oncology

Minneapolis, Minnesota, 55404, United States
National Cancer Center Hospital

Chuo Ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan
National Hospital Organization Kyushu Cancer Center

Fukuoka, 811-1395, Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Center

Osaka, 541-8567, Japan
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Rocky Mountain Cancer Centers

Lone Tree, Colorado, 80124, United States
Texas Oncology

Tyler, Texas, 75702, United States
University of Virginia

Charlottesville, Virginia, 22903, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.